Mark L. Ratner
In January, the GE Healthcare division of General Electric Co. announced its intention to buy Abbott Laboratories Inc. ’s core lab diagnostics business for $8.13 billion. [See Deal] For...
GE Grabs the Spotlight in IVD
The entry by GE into the core lab business via its acquisition of Abbott's clinical diagnostics businesses follows a similar move by Siemens last year, and suggests IVD may be best suited for generalist industrial giants. While the pricing pressures that have dogged this segment of diagnostics are not likely to abate, existing players--including Abbott--are continuing to develop high-margin molecular diagnostic tests that they expect the new players will want to incorporate into their platforms.
More from Business Strategy
• By
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
• By
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
• By
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
• By
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.